Tolerable and Effective Combination of Full-Dose Crizotinib and Osimertinib Targeting MET Amplification Sequentially Emerging after T790M Positivity in EGFR- Mutant Non–Small Cell Lung Cancer-Reference-Cited by-同舟云学术

Tolerable and Effective Combination of Full-Dose Crizotinib and Osimertinib Targeting MET Amplification Sequentially Emerging after T790M Positivity in EGFR- Mutant Non–Small Cell Lung Cancer

Published:2017-07 Issue:7 Volume:12 Page:e85-e88
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

York Emily R.^ORCID,Varella-Garcia Marileila,Bang Tami J.,Aisner Dara L.,Camidge D. Ross

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference12 articles.

1. Rociletinib in EGFR-mutated non-small-cell lung cancer;Sequist;N Engl J Med,2015

2. Good response to gefitinib in lung adenocarcinoma of complex epidermal growth factor receptor (EGFR) mutations with the classical mutation pattern;Wu;Oncologist,2008

3. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors;Sequist;Sci Transl Med,2011

4. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer;Jänne;N Engl J Med,2015

5. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling;Engelman;Science,2007

Cited by 68 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Management of oligometastatic and oligoprogressive epidermal growth factor receptor mutated non-small cell lung cancer patients: state of the art of a combined approach;Exploration of Targeted Anti-tumor Therapy;2024-05-17

2. Non-small cell lung cancer: an update on emerging EGFR-targeted therapies;Expert Opinion on Emerging Drugs;2024-04-02

3. Safety and efficacy of SNK01 (autologous natural killer cells) in combination with cytotoxic chemotherapy and/or cetuximab after failure of prior tyrosine kinase inhibitor in non-small cell lung cancer: non-clinical mouse model and phase I/IIa clinical study;Journal for ImmunoTherapy of Cancer;2024-03

4. The Efficacy and Safety of Treating Acquired MET Resistance Through Combinations of Parent and MET Tyrosine Kinase Inhibitors in Patients With Metastatic Oncogene-Driven NSCLC;JTO Clinical and Research Reports;2024-02

5. Real-World Data on Combined EGFR-TKI and Crizotinib Treatment for Acquired and De Novo MET Amplification in Patients with Metastatic EGFR-Mutated NSCLC;International Journal of Molecular Sciences;2023-08-23